Biological Therapies for Cancer: Technologies and Global Markets
Report Highlights
The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.
Report Includes
- 29 data tables and 80 additional tables
- An updated review of the global markets of biological therapies for cancer treatment and related technologies
- Analyses of the global market trends, with data from 2020, estimates for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of the market size and revenue forecast for cancer biologics market and its sub-segments, and corresponding market share analysis by product type, cancer type, and geographic region
- Coverage of biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products
- Discussion of biological therapies products available in the market, industry structure, cancer markets in newly emerging therapeutics, and analysis of biosimilars drugs and their impact on the market
- Review of cancer statistics and epidemiology insights and SWOT analysis of various cancer biotherapeutics present in the market
- A look at major issues and trends with relate to the R&D of more effective cancer treatment, and new cancer therapeutics in development, and outlook on cancer clinical trials
- Key marketed drugs and recent approvals, sales statistics and past performance of the top selling biologics, and insight into their patent expiries
- Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
- Descriptive company profiles of the leading market participants, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.
Report Scope
This report provides an update on BIO048C Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2026. It discusses important biologics, market share by cancer type, products on the market, market share by company and statistical information for cancer types prevalent globally. It also includes current issues and trends affecting the industry, as well as factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.
The market and sales data for recent years give strong support for research and development (R&D) programs and the move toward biologic treatment for cancer, as well as within biologics toward human monoclonal antibodies, vaccines and CAR T-cell therapies. The biologic drug classes discussed in this report with special focus on cancer treatment are:
- Monoclonal antibodies.
- Vaccines.
- CAR T-cell therapies.
The following approaches to cancer therapeutics are excluded in the report:
- Chemotherapy.
- Alkylating agents.
- Antimetabolites.
- Cytotoxic agents.
- Plant derivatives and hormone therapy corticosteroids.
- Hormone antagonists/antagonists aromatase inhibitors.
- Radiation therapy.
- Adjunctive and Supportive therapy.
- Interferons and Interleukins.
- Other immunostimulants.
Biological therapies for the treatment of other diseases will not be addressed in this report.
The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
- Treatment trends and sales patterns across major cancer indications for U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
- Market performance of major pharmaceutical companies.
- Sales of leading cancer products across major indications from 2018 to 2020.
- Biosimilars and their impact on currently marketed cancer biotherapeutics.
- Competitor landscape and share analysis.
This updated report includes the following new information:
- The latest version of the report provides elaborated information of cancer biologics market at a regional level. The current report provides regional and country-level market segmentation for the U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
- The latest version of the report provides elaborated information of competitor landscape and company share analysis.
- The latest version of the report also provides elaborated information on the novel CAR T-cell therapies.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.
Report Includes
- An overview of the global markets and technologies for biological therapies for cancer
- Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.
- Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.
- A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
- Comprehensive profiles of major players in the cancer biotherapeutics field.
Report Highlights
-
The global market for biological therapies for cancer was worth $37.9 billion in 2009, down from $38 billion in 2008. This number is expected to increase at a compound annual growth rate (CAGR) of 7.2% to reach $53.7 billion in 2014.
-
The U.S. market for biological therapies for cancer was worth $17.7 billion in 2009, down from $18.8 billion in 2008. This number is expected to increase at a compound annual growth rate (CAGR) of 6.2% to reach $23.9 billion in 2014.
-
The market for biological therapies for cancer in Europe and the rest of the world was worth $15.6 billion in 2009, down from $17.6 billion in 2008. This number is expected to increase at a compound annual growth rate (CAGR) of 7.8% to reach $22.8 billion in 2014.
Report Highlights
-
The current worldwide market for therapeutics from transgenic sources is zero, but is expected to exceed $1 billion in 2008 and reach $18.6 billion in 2013.
-
the projection for 2013.